Biomechanical Precision Medicine Registry for Patients With & Without

Status Recruiting

Clinical Trial Summary

In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.

Clinical Trial Description

Patients 18-years and older with and without heart failure (across all left ventricular ejection fraction) and cardiomyopathies including amyloidosis will be enrolled in this single center, longitudinal observational Registry. Baseline and one-year follow up blood samples including DNA as well as clinical characteristics, events leading up to heart failure diagnosis, etiology of heart failure, the presence and duration of other medical problems, laboratory, echocardiographic data and images, and therapy information will be obtained. Clinical outcomes of interest include major adverse cardiovascular events (a combination of all-cause death and heart failure hospitalizations), individual endpoints of all-cause death, cardiovascular death, all-cause hospitalization, cardiovascular hospitalization, heart failure hospitalization, right-sided heart failure, and kidney injury. Results from the Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) trial will comprehensively examine longitudinal clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand pathophysiology of heart failure and phenotypes in heart failure with an ultimate goal of improving precision medicine in heart failure. ;

Study Design

Related Conditions & MeSH terms

Cardiovascular Risk Factor
Heart Failure
Heart Failure With Mid Range Ejection Fraction
Heart Failure With Normal Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Heart Failure, Right Sided

Clinical Trial Details

NCT number	NCT03480633
Study type	Observational [Patient Registry]
Source	Massachusetts General Hospital
Contact	Abbie Macher, BS
Phone	617-643-6328
Email	ajmacher@mgh.harvard.edu
Status	Recruiting
Phase
Start date	April 7, 2016
Completion date	October 6, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03644524` - Heat Therapy and Cardiometabolic Health in Obese Women	N/A
Enrolling by invitation	`NCT04253054` - Chinese Multi-provincial Cohort Study-Beijing Project
Completed	`NCT03680638` - The Effect of Antioxidants on Skin Blood Flow During Local Heating	Phase 1
Recruiting	`NCT04481503` - Transthoracic Echocardiography of Ventricular Function of Parturients in Labor
Terminated	`NCT04088240` - Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease	N/A
Completed	`NCT03410342` - The Effects of Types of Fruits and Vegetables on Vascular Function	N/A
Completed	`NCT03170752` - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)	N/A
Recruiting	`NCT04231838` - Metabolic Syndrome in Diabetic Smokers Using Cigarettes & Combustion-Free Nicotine Delivery Systems	N/A
Active, not recruiting	`NCT03902431` - Translating the ABCS Into HIV Care	N/A
Terminated	`NCT03517111` - The Impact of a Parenting Intervention on Latino Youth Health Behaviors	N/A
Completed	`NCT04562467` - The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk	Phase 4
Completed	`NCT03429920` - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors	N/A
Completed	`NCT04551872` - RESILIENCE: Personalizing Cardiovascular Health	N/A
Enrolling by invitation	`NCT03314818` - Natural History of Carotid Plaque as Determined by 3D Ultrasound	N/A
Completed	`NCT03060811` - Mediterranean Diet, Trimethylamine N-oxide (TMAO) and Anti-oxidants in Healthy Adults	N/A
Completed	`NCT04279704` - Overcoming Obstacles in Epigenetic Analysis of Human Twins
Completed	`NCT01050205` - The Healthy Lifestyle Project	N/A
Completed	`NCT03570840` - Pediatric Metabolic Syndrome Study
Completed	`NCT03039023` - Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans	N/A
Completed	`NCT03646175` - Choline Supplementation and Cardiovascular Health	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure — PREFER-HF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms